Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis

van Breeschoten, Jesper; Wouters, Michel W J M; Hilarius, Doranne L; Haanen, John B; Blank, Christian U; Aarts, Maureen J B; van den Berkmortel, Franchette W P J; de Groot, Jan-Willem B; Hospers, Geke A P; Kapiteijn, Ellen; Piersma, Djura; van Rijn, Roos S; Suijkerbuijk, Karijn P M; Blokx, Willeke A M; Ten Tije, Bert-Jan J; van der Veldt, Astrid A M; Vreugdenhil, Art; Boers-Sonderen, Marye J; van den Eertwegh, Alfonsus J M

doi:https://doi.org/10.1038/s41416-021-01312-1

Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis

DSpace/Manakin Repository

Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis

van Breeschoten, Jesper; Wouters, Michel W J M; Hilarius, Doranne L; Haanen, John B; Blank, Christian U; Aarts, Maureen J B; van den Berkmortel, Franchette W P J; de Groot, Jan-Willem B; Hospers, Geke A P; Kapiteijn, Ellen; Piersma, Djura; van Rijn, Roos S; Suijkerbuijk, Karijn P M; Blokx, Willeke A M; Ten Tije, Bert-Jan J; van der Veldt, Astrid A M; Vreugdenhil, Art; Boers-Sonderen, Marye J; van den Eertwegh, Alfonsus J M

(2021) British Journal of Cancer, volume 124, issue 10

(Comment)

Abstract

Correction to: British Journal of Cancer https://doi.org/10.1038/s41416-020-01229-1, published online 26 January 2021

Download/Full Text

The full text of this publication is not available.

Version on publisher website for UU-students and staff

Version on publisher website

Keywords: Oncology, Cancer Research, Published Erratum

DOI: https://doi.org/10.1038/s41416-021-01312-1

ISSN: 0007-0920

Publisher: Nature Publishing Group

(Peer reviewed)